aTyr Pharma (ATYR) Competitors $5.25 -0.03 (-0.49%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$5.21 -0.04 (-0.84%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. SPRY, CNTA, TARS, BEAM, SRPT, ARQT, IMCR, SDGR, EVO, and OCULShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), Schrodinger (SDGR), Evotec (EVO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors ARS Pharmaceuticals Centessa Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Sarepta Therapeutics Arcutis Biotherapeutics Immunocore Schrodinger Evotec Ocular Therapeutix ARS Pharmaceuticals (NASDAQ:SPRY) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Do insiders and institutionals believe in SPRY or ATYR? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, SPRY or ATYR? ARS Pharmaceuticals has higher revenue and earnings than aTyr Pharma. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M18.16$8M-$0.16-103.03aTyr Pharma$230K2,033.07-$64.02M-$0.81-6.49 Do analysts prefer SPRY or ATYR? ARS Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 88.05%. aTyr Pharma has a consensus price target of $20.20, indicating a potential upside of 284.47%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is SPRY or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. ARS Pharmaceuticals' return on equity of -6.94% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-16.11% -6.94% -5.60% aTyr Pharma N/A -87.09%-64.77% Which has more volatility & risk, SPRY or ATYR? ARS Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Does the media refer more to SPRY or ATYR? In the previous week, ARS Pharmaceuticals had 8 more articles in the media than aTyr Pharma. MarketBeat recorded 12 mentions for ARS Pharmaceuticals and 4 mentions for aTyr Pharma. ARS Pharmaceuticals' average media sentiment score of 0.71 beat aTyr Pharma's score of 0.66 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryARS Pharmaceuticals beats aTyr Pharma on 11 of the 16 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$472.61M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-6.4921.5627.5220.22Price / Sales2,033.07281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book6.337.518.045.67Net Income-$64.02M-$55.05M$3.18B$249.13M7 Day Performance4.45%4.61%2.90%3.28%1 Month Performance-1.79%4.72%3.70%5.55%1 Year PerformanceN/A5.92%36.15%21.12% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.9814 of 5 stars$5.25-0.5%$20.20+284.5%N/A$472.61M$230K-6.4953Gap UpSPRYARS Pharmaceuticals3.2498 of 5 stars$17.45-4.1%$31.00+77.7%+81.4%$1.79B$89.15M-109.0690Insider TradeHigh Trading VolumeCNTACentessa Pharmaceuticals3.0445 of 5 stars$13.14+0.1%$27.89+112.2%+67.1%$1.75B$6.85M-7.26200TARSTarsus Pharmaceuticals2.2421 of 5 stars$40.51+0.4%$66.67+64.6%+42.0%$1.70B$182.95M-14.8450BEAMBeam Therapeutics2.7082 of 5 stars$17.01+1.3%$48.75+186.6%-14.7%$1.69B$63.52M-3.69510SRPTSarepta Therapeutics4.7322 of 5 stars$17.10-0.1%$60.88+256.0%-88.1%$1.68B$1.90B-6.361,372Trending NewsHigh Trading VolumeARQTArcutis Biotherapeutics2.0664 of 5 stars$14.02+2.0%$18.80+34.1%+42.9%$1.64B$196.54M-13.48150Positive NewsIMCRImmunocore2.3758 of 5 stars$31.38+0.8%$58.89+87.7%-8.4%$1.56B$310.20M-72.98320SDGRSchrodinger2.7999 of 5 stars$20.12-2.4%$32.80+63.0%+4.3%$1.51B$207.54M-7.65790Analyst ForecastHigh Trading VolumeEVOEvotec1.7225 of 5 stars$4.20+1.0%$5.93+41.3%-18.5%$1.48B$862.40M0.004,827News CoverageOCULOcular Therapeutix3.9378 of 5 stars$9.28+0.7%$17.33+86.8%+39.9%$1.47B$63.72M-8.07230 Related Companies and Tools Related Companies ARS Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives Sarepta Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Immunocore Alternatives Schrodinger Alternatives Evotec Alternatives Ocular Therapeutix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
